Abstract
In August 2008, lacosamide (Vimpat; UCB), was granted market authorization by the European Commission as an adjunctive therapy for partial-onset seizures with or without secondary generalization in patients with epilepsy. It was approved by the FDA as an adjunctive therapy for partial-onset seizures in October 2008.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Chang, B. S. & Lowenstein, D. H. Epilepsy. N. Engl. J. Med. 349, 1257–1266 (2003).
Diaz-Arrastia, R. et al. Evolving treatment strategies for epilepsy. JAMA 287, 17–20 (2002).
Perucca, E. et al. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 6, 793–804 (2007).
Löscher, W. & Schmidt, D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 17, 95–134 (1994).
Cortes, S. et al. Effect of structural modification of the hydantoin ring on anticonvulsant activity. J. Med. Chem. 28, 601–606 (1985).
Choi, D. et al. Synthesis and anticonvulsant activities of N-benzyl-2-acetamidopropionamide derivatives. J. Med. Chem. 39, 1907–1916 (1996).
Stöhr, T. et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 74, 147–154 (2007).
Beyreuther, B. K. et al. Lacosamide: a review of preclinical properties. CNS Drug Rev. 13, 21–42 (2007).
European Medicines Agency (EMEA). European Public Assessment Report – Vimpat. EMEA web site [online], (2008).
Food and Drug Administration (FDA). FDA labelling information. FDA web site [online], (2008).
Errington, A. C. et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol. 73, 157–169 (2008).
Ben-Menachem, E. et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48, 1308–1317 (2007).
Bialer, M. et al. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res. 73, 1–52 (2007).
Chung, S. S. et al. Lacosamide: efficacy and safety as oral adjunctive treatment for partial-onset seizures. Epilepsia 48, 321 (2007).
Perucca, E. Marketed new antiepileptic drugs: are they better than old-generation agents? Ther. Drug Monit. 24, 74–80 (2002).
Rauck, R. L. et al. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study, Clin. J. Pain 23, 150–158 (2007).
IMS MIDAS (2007).
Al-Wakeel, Y. et al. Credit Suisse Equity Research Report (Credit Suisse Securities Europe Ltd, 24 Sep 2008).
Bourdot, B. Deutsche Bank Global Market Research Report on UCB. (Deutsche Bank AG, 8 Jul 2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Emilio Perucca has received speaker's or consultancy fees and/or research grants from the manufacturers of carbamazepine and oxcarbazepine (Novartis); carisbamate and topiramate (Johnson & Johnson); eslicarbazepine (BIAL); ethosuximide, gabapentin, phenytoin and pregabalin (Pfizer); lamotrigine (GlaxoSmithKline); lacosamide and levetiracetam (UCB Pharma); retigabine (Valeant); tiagabine, valproic acid and vigabatrin (Sanofi-Aventis); rufinamide and zonisamide (Eisai).
Rights and permissions
About this article
Cite this article
Perucca, E., Yasothan, U., Clincke, G. et al. Lacosamide. Nat Rev Drug Discov 7, 973–974 (2008). https://doi.org/10.1038/nrd2764
Issue date:
DOI: https://doi.org/10.1038/nrd2764
This article is cited by
-
The effect of lacosamide monotherapy on sleep architecture in patients with epilepsy: a preliminary evidence
Journal of Neural Transmission (2023)
-
mTORC1-dependent translation of collapsin response mediator protein-2 drives neuroadaptations underlying excessive alcohol-drinking behaviors
Molecular Psychiatry (2017)
-
The Safety and Effectiveness of Intravenous Lacosamide for Refractory Status Epilepticus in the Critically Ill
Neurocritical Care (2017)
